外科，香港大学，薄扶林道，香港，中国

对于肝细胞癌患者来说，活体供肝肝移植（LDLT）是一个很好的选择，因为与尸体供肝肝移植（DDLT）相比，能够尽早的移除肿瘤。然而，活体肝移植的复发率明显更高。对于这种术后结果的差异可以用手术时机的不同来解释，因为只有肝癌增长速度缓慢的患者才能等待尸体肝移植。而且，最近亚洲一项以活体肝移植治疗肝癌的调查结果显示，活体肝移植的三年存活率大约为60%至80%。一些肝细胞癌患者因肝功能差而无法手术，从而采取药物治疗。研究人员经过比较发现，移植手术的疗效比药物治疗的疗效更好。以活体肝移植治疗肝细胞癌对患者来说是很好的选择，同时，也值得进行进一步的评估。

Live-donor liver transplantation for hepatocellular carcinoma
Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China.

Live-donor liver transplantation (LDLT) is a valuable option for patients with hepatocellular carcinoma (HCC) because compared with deceased-donor liver transplantation (DDLT), the tumor could be eradicated early. However, a higher incidence of recurrence is observed when the result is compared with DDLT. The difference is explained by the timing of transplant because only patients with slow HCC growth (and probably less aggressive tumors) can wait for DDLT. Nevertheless, a recent survey of results of LDLT for HCC in Asia indicated that the 3-year survival rate is approximately 60-80%, which is better than that of any treatment modalities for inoperable HCC associated with poor liver function. LDLT for HCC is still worthwhile to pursue and deserves further evaluation.

PMID: 17877494 [PubMed - in process]

[责任编辑:刘聪]